Previsioni

Il prezzo obiettivo medio degli analisti è +6,01€ (+92,63%). La mediana è +6,01€ (+92,63%).

Acquista	0
Mantieni	1
Vendi	0

Notizie Vai al feed delle notizie

Medexus Pharmaceuticals reports revenue decline in Q3 2026 due to competitive pressure

Medexus Pharmaceuticals recorded a net revenue decrease in the third quarter of 2026 from $30.0 million to $25.3 million, mainly due to intensified competition for Rupall. At the same time, gross margin improved to 53.6% and operating cash flow rose to $7.8 million, while cash on hand fell to $15.0 million. The company expects GRAFAPEX to generate positive cash flow by Q4 2026 and aims to secure increased reimbursement commitments over the next 12–18 months. » Altro su de.investing.com
Medexus Pharmaceuticals: Q2 revenue slightly down, gross margin improved

Medexus Pharmaceuticals reported Q2 net revenue of USD 24.7m (prior year USD 26.3m) with an improved gross margin of 55.7% (prior year 53.7%). Graphopex contributed USD 6.2m in six months, manufacturing costs for Ixinity were cut by 30%, and net debt was reduced to USD 11.7m. Adjusted EBITDA was USD 4.4m, net loss amounted to USD 0.3m, and cash fell to USD 9.4m. For Q3 the company expects Graphopex revenues of USD 2.5–3.5m and anticipates a positive cash-flow contribution by Q4 2025. » Altro su de.investing.com
Medexus Pharmaceuticals reports revenue decline but achieves record results for fiscal year 2025

Medexus Pharmaceuticals saw its revenue fall to $24.8 million in the fourth quarter of 2025, but achieved record EBITDA of $20.2 million and a record net profit for the full year. The launch of the new product Grafifex showed strong early performance, and the company expects Grafifex to generate positive cash flow by the end of 2026. The stock rose 2.13% following the earnings announcement. » Altro su de.investing.com

Dati finanziari dell'azienda

Nell'ultimo trimestre, Pediapharm ha registrato ricavi pari a 24,41 Mio€ e un utile netto di 464,55k€

(EUR)	giu 2026	YoY
Ricavi	+24,41 Mio	16,89%
Utile lordo	+13,52 Mio	15,69%
Utile netto	+464,55k	6,11%
EBITDA	+3,87 Mio	2,46%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	+101,08 Mio€
Numero di azioni	31,66 Mio
Massimo/minimo a 52 settimane	+3,40€ - +1,54€
Dividendi	No
Beta	1,69
Rapporto P/E	−48,59
Rapporto PEG	−0,60
Rapporto P/B	+2,48
Rapporto P/S	+1,15

Profilo aziendale

Medexus Pharmaceuticals Inc. ist als Spezialpharmaunternehmen in Kanada und den Vereinigten Staaten tätig. Das Unternehmen konzentriert sich auf die Therapiebereiche Onkologie, Hämatologie, Rheumatologie, Autoimmunerkrankungen und Allergien. Die wichtigsten Produkte des Unternehmens sind Rasuvo und Metoject, eine Formulierung von Methotrexat zur Behandlung von rheumatoider Arthritis und anderen Autoimmunkrankheiten, IXINITY, ein intravenöses rekombinantes Faktor-IX-Therapeutikum zur Anwendung bei Patienten ab 12 Jahren mit Hämophilie B, und Rupall, ein verschreibungspflichtiges Allergiemedikament. Zu seinem Produktportfolio gehören auch Treosulfan, ein bifunktionales Alkylierungsmittel für die allogene hämatopoetische Stammzelltransplantation, Trispan, eine injizierbare Triamcinolonhexacetonid-Suspension, und Gleolan, ein optisches Bildgebungsmittel für Patienten mit Gliomsymptomen. Das Unternehmen war früher als Pediapharm Inc. bekannt und änderte im Dezember 2018 seinen Namen in Medexus Pharmaceuticals Inc. Medexus Pharmaceuticals Inc. hat seinen Sitz in Bolton, Kanada.

Nome	Pediapharm
CEO	Kenneth d'Entremont
Sede centrale	Toronto, on Norvegia
Sito web	medexus.com
Settore	Servizi di pubblica utilità
Quotazione in borsa	19/08/2009
Dipendenti	90